A cervical cancer diagnosis can come suddenly — after an abnormal Pap smear that led to further investigations, or after symptoms that were investigated too late. However it arrived, your immediate priority is treatment, and the medical aid questions are urgent and practical. This guide gives you the steps in the right order.
You Have Cover — Here Is Why That Matters
Cervical cancer is a Prescribed Minimum Benefit (PMB) condition. Whatever your plan, whatever waiting periods might apply to other conditions, your medical aid is legally required to fund your diagnosis and treatment. The scheme cannot decline cervical cancer coverage. What varies between plans is the depth of that coverage — particularly the oncology sub-limit, which determines how much they will fund before the cost falls to you.
Step 1: Confirm Your PMB Oncology Registration
Call your scheme's member services and ask to be transferred to oncology case management (not the general call centre). Tell them:
- You have been diagnosed with cervical cancer.
- You need to register your PMB oncology benefit.
- Ask for a dedicated case manager to be assigned.
This registration ensures that your claims are correctly processed as PMB from the start — which matters enormously for what is paid out of your oncology sub-limit vs. what is funded separately as a PMB obligation.
Step 2: Find Out What Treatment You Need
Your treatment will depend on the stage of your cancer. This determines your medical aid experience significantly:
- Stage I (confined to cervix): Usually surgical — radical hysterectomy or, in some cases, trachelectomy (fertility-preserving). PMB-funded; plan your oncology sub-limit usage around specialist shortfalls, not medicine costs.
- Stage IB2 and above: Chemoradiation — concurrent cisplatin chemotherapy + external beam radiation + brachytherapy. This is intensive, multi-week treatment requiring pre-authorisation for each phase.
- Metastatic / recurrent disease: Systemic chemotherapy ± bevacizumab or pembrolizumab (both requiring exceptional-needs authorisation).
Ask your gynaecological oncologist to outline the treatment plan in writing so you can present it to your scheme's case manager for pre-authorisation.
Step 3: Find Your Oncology Sub-Limit
Check your plan documents or ask your case manager for your oncology sub-limit — the annual rand cap on cancer treatment. For early-stage cervical cancer managed with surgery, most plans are adequate. For Stage III chemoradiation or metastatic disease, costs escalate significantly:
- Stage I surgical treatment: R80,000–R200,000
- Stage II–III chemoradiation: R150,000–R400,000
- Stage IV with bevacizumab: R300,000–R600,000+
If your sub-limit appears insufficient for your projected treatment, you can move to a higher-benefit option within your current scheme without a new waiting period for your existing diagnosis. Do this before starting treatment if possible.
Step 4: Understand Radiation and DSP Requirements
Cervical cancer often requires brachytherapy (internal radiation) — a specialised procedure available only at certain oncology centres. Confirm with your case manager:
- Which facility is designated as your DSP for radiation therapy?
- Is the gynaecological radiation oncologist at that facility in the scheme's tariff?
- Is your treating gynaecological oncologist recognised by the scheme?
Using an out-of-network specialist or radiation facility for planned treatment can result in significant co-payments. This is worth confirming before treatment starts, not after the first bill arrives.
Step 5: Understand Your Medication Cover
Concurrent chemotherapy for cervical cancer is typically cisplatin — a generic, relatively low-cost platinum agent administered as weekly infusions during radiation. This is PMB-funded and scheme-costs are moderate.
For recurrent or metastatic disease, your oncologist may recommend: - Bevacizumab (Avastin): Not PMB; approximately R22,000–R30,000 per cycle. Requires exceptional-needs motivation. - Pembrolizumab (Keytruda): Not PMB; approximately R45,000–R70,000 per infusion. Requires PD-L1 testing result and exceptional-needs motivation.
If these agents are recommended, ask your oncologist to submit the exceptional-needs application at the same time as your initial PMB registration, not later. Turnaround is typically 5–15 business days.
Step 6: Should You Switch Plans?
If you are diagnosed early and your current plan's sub-limit is sufficient for your stage, there is usually no immediate reason to switch. However:
- If you are on an entry-level plan and diagnosed with Stage II–IV disease, consider moving to a higher-option plan within your scheme before treatment starts.
- Do not move to a new scheme after a cervical cancer diagnosis without specific financial advice. Pre-existing condition waiting periods and new-joiner processes apply.
- The October–November open-enrolment window is the main opportunity for option changes that take effect from 1 January.
What AURA Does Differently
AURA analyses your actual treatment requirements — stage, likely treatment protocol, sub-limit exposure — and shows you which plans genuinely cover this, not just which plans are cheapest.
Get help understanding your cover options →
Emergency Resources
CANSA (Cancer Association of SA): 0800 22 6622 (toll-free, weekdays) Patient navigation, counselling, support groups, and practical assistance.
Gynaecological Cancer Foundation: gynaeoncology.co.za Council for Medical Schemes (CMS): 0861 123 267 | www.medicalschemes.co.za For PMB disputes or unapproved claim appeals.